GMI-based biosensor for the detection and quantification of doxorubicin anticancer drugs labeled to Fe3O4 superparamagnetic nanoparticles

Basit Öğe Kaydı
dc.contributor.authorKirat, Gokhan
dc.contributor.authorErdogan, Ali
dc.contributor.authorAksan, Mehmet Ali
dc.date.accessioned2024-08-04T20:55:58Z
dc.date.available2024-08-04T20:55:58Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWe present the results of research on a Co -based giant magnetoimpedance (GMI) biosensor for Fe 3 O 4 -labelled doxorubicin (DOX) anticancer drugs. Co 62 Fe 5 Ni 4 Si 15 B 14 ribbons were used as biosensing material for test solutions containing different concentrations of DOX. The plain ribbon, ribbon +Fe 3 O 4 and ribbon +DOX2 samples exhibited low coercivity ( H c ), high saturation magnetization ( M s ) and low anisotropy ( H k ). The GMI ratio ( Delta Z / Z ) increased from 33% to 38% with the increase of doxorubicin content in the ribbon. It was found that the Delta Z / Z ratio first increased rapidly up to a frequency of -2 MHz, and then decreased slowly as the frequency increased. While the magnetic field dependent Delta Z / Z has a single peak at 1 MHz, it has a double peak at 5 MHz. It was found that the peak height of Delta Z/Z in the ribbons with test solution of 20 ng/ml and 50 ng/ml increased by -3% and -6%, respectively, compared to the ribbon without test solution. Then the Delta Z / Z ratio decreased very rapidly with the increase of the applied external magnetic fields. The frequency -dependent GMI sensitivity ( eta) increased with increasing frequency and reached a maximum value at a critical frequency (-1.6 MHz), after which it decreased. The detection sensitivity of the GMI biosensor ( xi ) increased rapidly with increasing doxorubicin concentration up to -80 ng/ml and then remained almost unchanged. The results show that doxorubicin (DOX +Fe 3 O 4 ), used as an anticancer drug, can be effectively detected even at low concentrations using the GMI based sensors fabricated in this study.en_US
dc.description.sponsorshipResearch Fund of Inonu University, Turkey [FBG-2022-2848, FCD-2018-767]en_US
dc.description.sponsorshipThis work was supported by the Research Fund of Inonu University, Turkey under Grant Contract No. FBG-2022-2848 and FCD-2018-767.en_US
dc.identifier.doi10.1016/j.sna.2024.115400
dc.identifier.issn0924-4247
dc.identifier.issn1873-3069
dc.identifier.scopus2-s2.0-85192261448en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.sna.2024.115400
dc.identifier.urihttps://hdl.handle.net/11616/101969
dc.identifier.volume373en_US
dc.identifier.wosWOS:001239317400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Science Saen_US
dc.relation.ispartofSensors and Actuators A-Physicalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiosensoren_US
dc.subjectMagnetoimpadanceen_US
dc.subjectMagnetic nanoparticleen_US
dc.subjectAmorphous ribbonen_US
dc.titleGMI-based biosensor for the detection and quantification of doxorubicin anticancer drugs labeled to Fe3O4 superparamagnetic nanoparticlesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu